US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
US4933447A
(en)
|
1987-09-24 |
1990-06-12 |
Ss Pharmaceutical Co., Ltd. |
Quinoline derivatives
|
US6001826A
(en)
|
1989-12-21 |
1999-12-14 |
Anormed, Inc. |
Chemical compounds
|
US5021409A
(en)
|
1989-12-21 |
1991-06-04 |
Johnson Matthey Plc |
Antiviral cyclic polyamines
|
GB9126677D0
(en)
|
1991-12-16 |
1992-02-12 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
GB9200245D0
(en)
|
1992-01-07 |
1992-02-26 |
British Bio Technology |
Compounds
|
US5235056A
(en)
|
1992-04-22 |
1993-08-10 |
Ciba-Geigy Corporation |
Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith
|
GB9400411D0
(en)
|
1994-01-11 |
1994-03-09 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
GB9511357D0
(en)
|
1995-06-06 |
1995-08-02 |
Johnson Matthey Plc |
Improved antiviral compounds
|
US6506770B1
(en)
|
1996-06-06 |
2003-01-14 |
Anormed, Inc. |
Antiviral compounds
|
AU6887996A
(en)
|
1995-09-01 |
1997-04-01 |
Washington University School Of Medicine |
Method of reducing neurotoxic injury with zinc chelators
|
EA001207B1
(ru)
|
1996-03-22 |
2000-12-25 |
Дюпон Фармасьютикалз Компани |
Способ получения r-альфа-пропил-пиперониламина и его аналогов, промежуточные продукты, используемые в этом способе
|
CN1231215C
(zh)
|
1997-06-02 |
2005-12-14 |
詹森药业有限公司 |
(咪唑-5-基)甲基-2-喹啉酮衍生物用作平滑肌细胞增殖抑制剂
|
WO1999004794A1
(en)
|
1997-07-25 |
1999-02-04 |
Merck & Co., Inc. |
Cyclic amine modulators of chemokine receptor activity
|
WO1999016747A1
(fr)
|
1997-09-30 |
1999-04-08 |
Daiichi Pharmaceutical Co., Ltd. |
Derives sulfonyle
|
GB9726229D0
(en)
|
1997-12-12 |
1998-02-11 |
Zeneca Ltd |
Resolution of chiral amines
|
AU748064B2
(en)
|
1997-12-19 |
2002-05-30 |
Takeda Chemical Industries Ltd. |
Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
|
US6607799B1
(en)
|
1998-10-15 |
2003-08-19 |
3M Innovative Properties Company |
Surgical dressing with delivery system and method of manufacture
|
US6635278B1
(en)
|
1998-12-15 |
2003-10-21 |
Gilead Sciences, Inc. |
Pharmaceutical formulations
|
TWI230618B
(en)
*
|
1998-12-15 |
2005-04-11 |
Gilead Sciences Inc |
Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
|
US6365583B1
(en)
|
1999-02-02 |
2002-04-02 |
Anormed, Inc. |
Methods to enhance white blood cell count
|
JP2003524620A
(ja)
|
1999-03-24 |
2003-08-19 |
アノーメッド インコーポレイティド |
ケモカインレセプター結合複素環化合物
|
US6245799B1
(en)
|
1999-11-08 |
2001-06-12 |
American Home Products Corp |
[(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
|
US6683192B2
(en)
|
2000-03-30 |
2004-01-27 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
EP1317445B1
(en)
|
2000-09-15 |
2009-03-11 |
Anormed Inc. |
Chemokine receptor binding heterocyclic compounds
|
EP1752455B1
(en)
|
2000-09-15 |
2010-11-10 |
Anormed Inc. |
Chemokine receptor binding heterocyclic compounds
|
CA2419219A1
(en)
|
2000-09-15 |
2002-03-21 |
Anormed Inc. |
Chemokine receptor binding heterocyclic compounds
|
AU2001297717B2
(en)
|
2000-12-11 |
2006-02-23 |
Amgen Inc. |
CXCR3 antagonists
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
GB0107228D0
(en)
|
2001-03-22 |
2001-05-16 |
Astrazeneca Ab |
Chemical compounds
|
US6794379B2
(en)
|
2001-06-06 |
2004-09-21 |
Tularik Inc. |
CXCR3 antagonists
|
SI2371361T1
(sl)
|
2001-07-31 |
2019-10-30 |
Genzyme Corp |
Metode za mobilizacijo predniških/matičnih celic
|
US7169750B2
(en)
|
2001-07-31 |
2007-01-30 |
Anormed, Inc. |
Methods to mobilize progenitor/stem cells
|
US8178123B2
(en)
|
2001-08-29 |
2012-05-15 |
Femina Pharma Incorporated |
Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
|
PL372705A1
(en)
|
2001-09-12 |
2005-07-25 |
Anormed Inc. |
Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
|
US7354932B2
(en)
|
2001-12-21 |
2008-04-08 |
Anormed, Inc. |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
IL161784A0
(en)
|
2001-12-21 |
2005-11-20 |
Anormed Inc |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
US7491544B2
(en)
|
2002-05-20 |
2009-02-17 |
New York University |
Chiral piperidine and quinucledine ligands
|
DE60325740D1
(de)
|
2002-08-14 |
2009-02-26 |
Silence Therapeutics Ag |
Verwendung von protein-kinase-n-beta
|
JP4666256B2
(ja)
|
2002-12-10 |
2011-04-06 |
小野薬品工業株式会社 |
含窒素複素環化合物およびその医薬用途
|
US7291631B2
(en)
|
2003-04-11 |
2007-11-06 |
Genzyme Corporation |
CXCR4 chemokine receptor binding compounds
|
WO2004093817A2
(en)
|
2003-04-22 |
2004-11-04 |
Anormed Inc. |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
US7501518B2
(en)
|
2003-04-22 |
2009-03-10 |
Genzyme Corporation |
Methods of making 2,6-diaryl piperidine derivatives
|
US7498346B2
(en)
|
2003-12-11 |
2009-03-03 |
Genzyme Corporation |
Chemokine receptor binding compounds
|
CN1930127B
(zh)
|
2004-03-15 |
2012-11-21 |
阿诺麦德股份有限公司 |
用于合成cxcr4拮抗剂的方法
|
WO2005100340A2
(en)
|
2004-04-13 |
2005-10-27 |
Icagen, Inc. |
Polycyclic pyridines as potassium ion channel modulators
|
DE102004021716A1
(de)
|
2004-04-30 |
2005-12-01 |
Grünenthal GmbH |
Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
|
MX2007001514A
(es)
|
2004-08-02 |
2007-03-27 |
Smithkline Beecham Corp |
Compuestos quimicos.
|
JP2008510006A
(ja)
|
2004-08-16 |
2008-04-03 |
スミスクライン ビーチャム コーポレーション |
化合物
|
JP2008511669A
(ja)
|
2004-09-02 |
2008-04-17 |
スミスクライン ビーチャム コーポレーション |
化合物
|
JP2008514622A
(ja)
|
2004-09-24 |
2008-05-08 |
スミスクライン ビーチャム コーポレーション |
化合物
|
TW200619206A
(en)
|
2004-09-29 |
2006-06-16 |
Anormed Inc |
Chemokine-binding heterocyclic compound salts, and methods of use thereof
|
EP1853604A4
(en)
|
2005-03-04 |
2010-02-24 |
Smithkline Beecham Corp |
CHEMICAL COMPOUNDS
|
EP1904645B1
(en)
|
2005-07-08 |
2010-08-04 |
Siemens Healthcare Diagnostics GmbH |
Method for predicting and monitoring direct response to cancer therapy
|
JP2009500451A
(ja)
|
2005-07-11 |
2009-01-08 |
スミスクライン ビーチャム コーポレーション |
ピラノピリジン化合物
|
BRPI0614256B1
(pt)
|
2005-08-02 |
2018-10-16 |
Ineos Europe Ltd |
processo para a produção de homopolímeros ou copolímeros de dienos conjugados
|
JP2009507795A
(ja)
|
2005-08-31 |
2009-02-26 |
スミスクライン ビーチャム コーポレーション |
化合物
|
EP1961744B1
(en)
|
2005-11-18 |
2013-04-17 |
Ono Pharmaceutical Co., Ltd. |
Basic group-containing compound and use thereof
|
AR063656A1
(es)
|
2005-11-30 |
2009-02-11 |
Schering Corp |
Composiciones que comprenden una combinacion de antagonistas de ccr5 y cxcr4
|
EP1984376A4
(en)
|
2006-01-25 |
2009-04-08 |
Smithkline Beecham Corp |
CHEMICAL COMPOUNDS
|
EP1984375A2
(en)
|
2006-01-25 |
2008-10-29 |
Smithkline Beecham Corporation |
Chemical compounds
|
GB0605786D0
(en)
|
2006-03-22 |
2006-05-03 |
Glaxo Group Ltd |
Compounds
|
BRPI0712843A2
(pt)
|
2006-06-12 |
2012-07-31 |
Pfizer Prod Inc |
antagonista de ccr5 e seus usos
|
TWI482772B
(zh)
|
2006-08-21 |
2015-05-01 |
Astrazeneca Ab |
適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
|
WO2008141239A1
(en)
|
2007-05-10 |
2008-11-20 |
Acadia Pharmaceuticals Inc. |
Imidazol [1,2-a] pyridines and related compounds with activity at cannabinoid cb2 receptors
|
WO2009026251A1
(en)
|
2007-08-17 |
2009-02-26 |
The General Hospital Corporation |
Detecting ions and measuring ion concentrations
|
MX2010010619A
(es)
|
2008-03-28 |
2010-12-17 |
Altiris Therapeutics |
Moduladores de quimioquina.
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
JP2010016628A
(ja)
|
2008-07-03 |
2010-01-21 |
Canon Inc |
画像処理装置及び画像処理方法
|
EA201692167A1
(ru)
|
2008-12-09 |
2017-07-31 |
Джилид Сайэнс, Инк. |
Модуляторы толл-подобных рецепторов
|
US9119790B2
(en)
|
2009-09-28 |
2015-09-01 |
Zenbury International Limited |
Pharmaceutical composition
|
CA2706292A1
(en)
|
2010-05-28 |
2011-11-28 |
Pharmascience Inc. |
A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
|
US20110293521A1
(en)
|
2010-05-28 |
2011-12-01 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Anti-viral compositions and methods for administration
|
US9155723B2
(en)
|
2010-06-28 |
2015-10-13 |
The General Hospital Corporation |
Anti-CXCR4 as a sensitizer to cancer therapeutics
|
GB201017345D0
(en)
|
2010-10-14 |
2010-11-24 |
Proximagen Ltd |
Receptor antagonists
|
US9267934B2
(en)
|
2010-10-26 |
2016-02-23 |
University Of South Alabama |
Methods and compositions for ameliorating pancreatic cancer
|
US8969381B2
(en)
|
2010-12-03 |
2015-03-03 |
Emory University |
Chemokine CXCR4 receptor modulators and used related thereto
|
EP2648754A4
(en)
|
2010-12-07 |
2016-02-24 |
Philadelphia Health & Educatio |
METHODS OF INHIBITING THE METASTASIS OF CANCER
|
TR201820015T4
(tr)
|
2010-12-09 |
2019-01-21 |
Univ Pennsylvania |
Kanser Tedavisi İçin Kimerik Antijen Reseptörü-Modifiye Edilmiş T Hücrelerinin Kullanılması
|
JP6087836B2
(ja)
|
2011-01-11 |
2017-03-01 |
ディメリックス バイオサイエンス プロプライアタリー リミテッド |
併用療法
|
MX365242B
(es)
*
|
2011-05-16 |
2019-05-28 |
Genzyme Corp |
El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.
|
AR087364A1
(es)
|
2011-07-29 |
2014-03-19 |
Pf Medicament |
Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
EP2802315A1
(en)
|
2012-01-12 |
2014-11-19 |
Gilead Sciences, Inc. |
Pharmaceutical compositions and methods for their preparation
|
US20150301058A1
(en)
|
2012-11-26 |
2015-10-22 |
Caris Science, Inc. |
Biomarker compositions and methods
|
US10064826B2
(en)
|
2013-03-15 |
2018-09-04 |
Navinta, Llc |
Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
|
AU2014274864B2
(en)
|
2013-06-05 |
2018-10-18 |
Salk Institute For Biological Studies |
Vitamin D receptor agonists to treat diseases involving CXCL12 activity
|
WO2015019284A2
(en)
|
2013-08-05 |
2015-02-12 |
Cambridge Enterprise Limited |
Inhibition of cxcr4 signaling in cancer immunotherapy
|
JP2016529293A
(ja)
*
|
2013-08-27 |
2016-09-23 |
ギリアド ファーマセット エルエルシー |
2つの抗ウイルス化合物の組合せ製剤
|
CA3206628A1
(en)
|
2013-09-12 |
2015-03-19 |
Dana-Farber Cancer Institute, Inc. |
Methods for evaluating and treating waldenstrom's macroglobulinemia
|
WO2015069770A1
(en)
|
2013-11-05 |
2015-05-14 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
US10280183B2
(en)
|
2014-03-18 |
2019-05-07 |
The Research Foundation For The State University Of New York |
Therapeutic agent for treating tumors
|
AU2015231413B2
(en)
|
2014-03-19 |
2020-04-23 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
|
EP3157921A1
(en)
|
2014-06-23 |
2017-04-26 |
Dr. Reddy's Laboratories Ltd. |
Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
|
HUE045108T2
(hu)
|
2014-07-16 |
2019-12-30 |
Transgene Sa |
Onkolitikus vírus immunellenõrzõpont-modulátorok expresszálására
|
WO2016146143A1
(en)
|
2015-03-16 |
2016-09-22 |
Amal Therapeutics Sa |
Cell penetrating peptides and complexes comprising the same
|
CN108026173A
(zh)
|
2015-06-12 |
2018-05-11 |
百时美施贵宝公司 |
通过联合阻断pd-1和cxcr4信号传导途径治疗癌症
|
AU2016322552B2
(en)
|
2015-09-14 |
2021-03-25 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
US10379661B2
(en)
|
2015-09-25 |
2019-08-13 |
Samsung Electronics Co., Ltd. |
Coordinate measuring apparatus and coordinate measuring system having the same
|
JP6958820B2
(ja)
|
2015-12-14 |
2021-11-02 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
がんを処置する方法
|
JP6864296B2
(ja)
*
|
2015-12-14 |
2021-04-28 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
がんを処置する方法
|
US10610527B2
(en)
|
2015-12-22 |
2020-04-07 |
X4 Pharmaceuticals, Inc. |
Methods for treating immunodeficiency disease
|
CA3010617A1
(en)
|
2016-01-22 |
2017-07-27 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
CN109153722A
(zh)
|
2016-04-08 |
2019-01-04 |
X4 制药有限公司 |
用于治疗癌症的方法
|
WO2017181073A1
(en)
|
2016-04-14 |
2017-10-19 |
Creatv Microtech, Inc. |
Methods of using pd-l1 expression in treatment decisions for cancer therapy
|
EP3471727B1
(en)
|
2016-06-21 |
2020-12-09 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
WO2017223243A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
WO2017223229A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
CN110996952A
(zh)
|
2017-06-21 |
2020-04-10 |
X4 制药有限公司 |
用于治疗癌症的方法
|
WO2019094392A1
(en)
|
2017-11-07 |
2019-05-16 |
X4 Pharmaceuticals, Inc. |
Cancer biomarkers and methods of use thereof
|
US20210009557A1
(en)
|
2017-12-19 |
2021-01-14 |
X4 Pharmaceuticals, Inc. |
Acyclic cxcr4 inhibitors and uses thereof
|
WO2019200223A1
(en)
|
2018-04-13 |
2019-10-17 |
X4 Pharmaceuticals, Inc. |
Cancer serum biomarkers and methods of use thereof
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|